XML 39 R34.htm IDEA: XBRL DOCUMENT v3.25.3

Segment Reporting (Tables)

9 Months Ended

Sep. 30, 2025

Segment Reporting [Abstract]

Schedule of Segment Reported Segment Revenues, and Significant Segment Expenses

The following table presents information about reported segment revenues, and significant segment expenses as provided to the CODM.

		Three Months Ended September 30,				Three Months Ended September 30,				Nine Months Ended September 30,				Nine Months Ended September 30,
		2025				2024				2025				2024
Revenue:
Product revenue, net		$	13,129			$	9,300			$	36,219			$	11,564
Total revenue			13,129				9,300				36,219				11,564
Operating costs and expenses:
Cost of product revenue			1,088				806				2,607				894
Direct, external research and development expenses by program:
Pemivibart			333				4,637				2,629				27,936
VYD2311			265				45,045				2,778				64,175
Adintrevimab			41				128				368				475
Total direct, external research and development expenses by program			639				49,810				5,775				92,586
Unallocated research and development expenses(1)			6,585				7,108				20,046				23,261
Other segment items(2)			12,767				11,021				41,717				35,739
Stock-based compensation			3,073				2,866				9,079				16,731
Total operating costs and expenses			24,152				71,611				79,224				169,211
Loss from operations			(11,023	)			(62,311	)			(43,005	)			(157,647	)
Other income:
Other income, net(3)			553				1,572				1,586				6,165
Total other income, net			553				1,572				1,586				6,165
Net loss		$	(10,470	)		$	(60,739	)		$	(41,419	)		$	(151,482	)

(1)Includes personnel related expenses (excluding research and development stock-based compensation) and external discovery-related and other costs.

(2)Includes commercial, general and administrative personnel related costs (excluding stock-based compensation), professional and consulting fees and other costs.

Includes interest income of $554 and $1,563 for the three months ended September 30, 2025 and 2024, respectively and interest income of $1,587 and $6,325 for the nine months ended September 30, 2025 and 2024, respectively.

X

- Definition

Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 25
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-25

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-30

+ Details

Name:	us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	us-gaap_SegmentReportingAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration